Skip to main content

Medpace Holdings, Inc.

corporate_fare Company Profile

Medpace Holdings, Inc.

MEDP·NASDAQ·Industrial Applications And Services·CIK 0001668397

Medpace Holdings, Inc. is a global clinical contract research organization (CRO) that provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company's mission is to accelerate the global development of safe and effective medical therapeutics. Medpace focuses on delivering full-service Phase I-IV clinical development services, emphasizing a disciplined operating model and therapeutic expertise to provide timely and cost-effective results. Medpace aims to be a partner of choice for small and mid-sized biopharmaceutical companies, consistently utilizing its full-service, disciplined operating model to deliver high-quality results. The company's business strategy involves expanding its market share in the growing Phase I-IV CRO market by conducting clinical trials across all major therapeutic areas. Medpace demonstrates particular strength in Oncology, Metabolic, Cardiology, Antiviral and Anti-infective (AVAI), and Central Nervous System (CNS). The company generates revenue by offering a full suite of services that support the entire clinical development process, from Phase I to Phase IV, across various therapeutic areas. Before a new drug can be commercialized, it typically undergoes extensive pre-clinical and clinical testing and regulatory review to verify safety and efficacy. Medpace's services include a medical department with therapeutic leads who provide strategic direction for study design and planning, train operational staff, work with primary investigators, offer medical monitoring, and meet with regulatory agencies. Clinical trial management is led by clinical trial managers (CTMs) who oversee all aspects of study execution and drive accountability. CTMs utilize ClinTrak, Medpace's proprietary information management system for clinical trials, which is integrated with standard operating procedures (SOPs) to provide real-time study metrics.

Medpace Holdings, Inc. (NASDAQ:MEDP) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for MEDP at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Medpace Reports Strong Q4 & Full Year 2025 Results, Provides Decelerated 2026 Guidance

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.53B
Net Income
$451.12M
Diluted EPS
$15.28
Op. Cash Flow
$713.22M
Free Cash Flow
$681.87M
Operating Income
$534.93M
Cash & Equivalents
$497.05M
Debt / Equity
0.00×
Net Margin
17.8%
Shares Outstanding
28.37M sh
Source: 10-K · filed 2026-02-10 · accession 0001668397-26-000006
$605.49 -0.83% today
52-week range · as of 2026-10-22 $373 – $684.52
Market cap
$17.08B
Volume
236.8K (0.8× avg)
3-mo avg 283.9K
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MEDP - Filings & News (Page 2)

MEDP
Feb 09, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $502.01
Real-time Price: $605.49 info
Change: +$103.48 (+21%) info
Market Cap: $17.078B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets